LISBON, Portugal, Sept. 01, 2023 -- SOMAÍ Pharmaceuticals Unipessoal LDA, a leading European pharmaceutical and biotech company specializing in cannabinoid-containing products, announced that it has received the European Union-Good Manufacturing Practice (EU-GMP) certification from the Portuguese health authority. This certification allows the company to distribute its cannabis products throughout Europe, ensuring high quality and safety standards for consumers.
The company plans to establish distribution channels for its Portuguese cannabis in Australia and Germany, expanding its reach and providing patients in these countries with access to medical cannabis products. This move marks a significant step forward for SOMAÍ Pharmaceuticals in its mission to provide patients with high-quality, pharmaceutical-grade cannabis products.
Lucas Davis, manager of Lisbon Cannabis Company, points to Charlotte's Web, a CBD flower that is good for someone with chronic pain, as a popular product among their customers. With the EU-GMP certification, the company can now offer a wider range of cannabis products to meet the needs of patients with various medical conditions.
Maine's adult-use cannabis stores are set to open on October 9, with Leafly mapping them on its app for easy access. This development highlights the growing acceptance and legalization of cannabis products in different parts of the world, including Europe.
AceCann, another cannabis company, recently closed a $15 million seed financing round to produce premium, organic flower and extracts for the European market. This funding will accelerate the development of new products and technologies to meet the growing demand for cannabis products in Europe.
Lisbon's medical marijuana stores have reported an increase in sales during the coronavirus pandemic, as patients seek alternative treatments for their medical conditions. This trend underscores the importance of access to medical cannabis products for patients who rely on them for relief.
In the United States, a rapper has made a name for himself in the cannabis industry as the co-founder of Casa Verde, a venture capital fund based in Los Angeles that focuses on investing in cannabis-related businesses. This shows the growing interest and investment opportunities in the cannabis industry worldwide.
Overall, the cannabis industry is experiencing significant growth and expansion, with companies like SOMAÍ Pharmaceuticals leading the way in providing high-quality cannabis products to patients in Europe and beyond. With the EU-GMP certification, Lisbon Cannabis Company is well-positioned to meet the growing demand for medical cannabis products and improve access for patients in need.
